China targets hospital formulary barriers for eligible innovative drugs
A four-agency notice addresses formulary limits, hospital performance metrics and payment exceptions for eligible innovative drugs. Uptake remains to be demonstrated.
Desk brief
Same-day short English notes.
BrightGene reports a Phase 3 glucose-control edge over semaglutide 1 mg
BrightGene reports a 32-week HbA1c advantage for BGM0504 10 mg over semaglutide 1 mg. The diabetes program still needs a filing and approval.
Haisco opened a China Phase 3 for an oral IL-23. The category leader is already a pill.
HSK47388 entered Phase 3 in plaque psoriasis on China’s registry—about 390 patients, PASI 90 at week 16. J&J’s oral IL-23 receptor peptide is already approved in the US and Europe.
Qilu registered a Phase 3 for its Claudin6 ADC. The trial has not started.
QLS5132 is the first Claudin6 ADC to post a Phase 3—in platinum-resistant ovarian cancer, 420 patients, PFS and OS. ClinicalTrials.gov still lists it as not yet recruiting.
China cleared Lilly’s weight-loss pill a week after CIIE. The BMI line stayed American.
Orforglipron is China’s first oral GLP-1 for weight loss. The NMPA label still starts at BMI 27/30, while Novo’s injection was rewritten last month to China’s 24/28 scale.
AASLD 2026: MASH strategies split between GLP-1s and liver-fat siRNA
Survodutide and semaglutide analyses probe benefit beyond weight loss; Regeneron/Alnylam’s ALN-CIDEB reports large liver-fat cuts.
HighField’s TLL-018 tops tofacitinib on ACR50 in Phase 3 RA
Late-breaking ACR data: JAK1/TYK2 inhibitor ginoxitinib posted a 73% ACR50 rate at week 24 versus 49.5% for tofacitinib.